Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer

被引：1

作者：

Dong Wang ^{[1
]}

Ruikai Du ^{[1
]}

Suling Liu ^{[2
,3
]}

机构：

[1] The CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at the Microscale,School of Life Science and Medical Center,University of Science &Technology of China

[2] Key Laboratory of Breast Cancer in Shanghai,Cancer Institute,Department of Breast Surgery,Fudan University Shanghai Cancer Center

[3] Institutes of Biomedical Sciences,Fudan University

来源：

Chinese Journal of Cancer | 2017年 / 36卷 / 06期

关键词：

PARP; on; BRCA; TNBC; Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer; in; stem;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

<正>Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene,and its protein BRCA1 plays a role in DNA repair[1].BRCA1 is generally expressed in the cells of mammary glands and other tissues,helping to repair damaged DNA or disrupting cells when DNA cannot be repaired.When BRCA1 is mutated and cannot function and therefore the damaged DNA cannot be repaired on

引用

页码：245 / 246

页数：2

共 7 条

[1]

PARP inhibitors: its role in treatment of cancer[J]. Alice Chen.癌症. 2011(07)

[2] RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer [J].

Liu, Yajing ;

Burness, Monika L. ;

Martin-Trevino, Rachel ;

Guy, Joey ;

Bai, Shoumin ;

Harouaka, Ramdane ;

Brooks, Michael D. ;

Shang, Li ;

Fox, Alex ;

Luther, Tahra K. ;

Davis, April ;

Baker, Trenton L. ;

Colacino, Justin ;

Clouthier, Shawn G. ;

Shao, Zhi-ming ;

Wicha, Max S. ;

Liu, Suling .

CLINICAL CANCER RESEARCH, 2017, 23 (02) :514-522

[3] ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer [J].

Papadaki, Chara ;

Sfakianaki, Maria ;

Ioannidis, Georgios ;

Lagoudaki, Eleni ;

Trypaki, Maria ;

Tryfonidis, Kostas ;

Mavroudis, Dimitris ;

Stathopoulos, Efstathios ;

Georgoulias, Vassilis ;

Souglakos, John .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (04) :663-671

[4]

ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays[J] . Yifang Hu,Gordon K. Smyth.Journal of Immunological Methods . 2009 (1)

[5] ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J].

Ginestier, Christophe ;

Hur, Min Hee ;

Charafe-Jauffret, Emmanuelle ;

Monville, Florence ;

Dutcher, Julie ;

Brown, Marty ;

Jacquemier, Jocelyne ;

Viens, Patrice ;

Kleer, Celina G. ;

Liu, Suling ;

Schott, Anne ;

Hayes, Dan ;

Birnbaum, Daniel ;

Wicha, Max S. ;

Dontu, Gabriela .

CELL STEM CELL, 2007, 1 (05) :555-567

[6] The Rad51/RadA N-terminal domain activates nucleoprotein filament ATPase activity [J].

Galkin, Vitold E. ;

Wu, Yan ;

Zhang, Xiao-Ping ;

Qian, Xinguo ;

He, Yujiong ;

Yu, Xiong ;

Heyer, Wolf-Dietrich ;

Luo, Yu ;

Egelman, Edward H. .

STRUCTURE, 2006, 14 (06) :983-992

[7] Cancer susceptibility and the functions of BRCA1 and BRCA2 [J].

Venkitaraman, AR .

CELL, 2002, 108 (02) :171-182

← 1 →